Recall: D-0853-2026
Class II - Potentially Harmful
Class IIClassification
2026-09-04Initiated
OngoingStatus
PfizerFirm
Product
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
Reason
Lack of Assurance of Sterility
Distribution
US Nationwide.
Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.